AD/PD 2021 | ALZ-801: oral anti-amyloid agent for Alzheimer’s disease

ALZ-801, a prodrug of tramiprosate, is an oral agent that selectively and dose-dependently inhibits the formation of soluble beta-amyloid (Aβ) oligomers. Marwan Sabbagh, MD, Lou Ruvo Center for Brain Health, Las Vegas, NV, discusses the mechanism of action of ALZ-801 and what makes it distinct from other anti-amyloid agents, such as monoclonal antibodies. ALZ-801 showed significant clinical effects in a Phase II trial in the high-risk population of patients homozygous for the ε4 allele of apolipoprotein E gene (APOE4). The agent will be further evaluated in the Phase III APOLLOE4 trial (NCT04770220) in patients with early Alzheimer’s disease who are homozygous for APOE4 genotype. This interview took place during the AD/PD™ 2021 conference.